Prostate Cancer Coalition of New Hampshire

News You Can Use – August 2021

By

mpMRI Misses Few Significant Prostate Cancers in Re-Biopsied Men

Obesity Linked to Lower Death Risk in mCRPC

EAU 2021: De Novo Versus Recurrent Metastatic mHSPC: What Is the Role of Modern Imaging?

EAU 2021: Phase 3 Study of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer (VISION)

EAU 2021: TheraP Phase 2 Trial of Lu-PSMA-617 vs Cabazitaxel: Results and Contrasts to the VISION Study

EAU 2021: Introduction and Setting the Stage: Prostate Cancer: cN+ in Newly Diagnosed Patients

EAU 2021: Monitoring and When To Change Treatment In mHSPC

EAU 2021: Tumor Molecular Testing: For Whom and When Is It Clinically Useful?

EAU 2021: PSMA In Diagnostics and Treatment

Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.

The stanford prostate cancer calculator: Development and external validation of online nomograms incorporating PIRADS scores to predict clinically significant prostate cancer.

Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing.

Pathologic Outcomes in Prostate Cancer Cases Worsened During Pandemic

Apalutamide Prolongs Survival in mCSPC Regardless of Disease Volume

PSMA-PET/CT May Detect Prostate Cancer More Accurately Than mpMRI

Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort.

Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223.

Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness.

The added value of PSMA PET/MR radiomics for prostate cancer staging.

MRI Can Avoid Unnecessary Prostate Biopsies Among Screened Men

Low Carbohydrate Diets and Estimated Cardiovascular and Metabolic Syndrome Risk in Prostate Cancer.